

*

250031

: -35 :

60 n=30 -35 n=30

-35 LH

FSH/LH P 0.05 T LH FSH/LH

P 0.05 P [0.42 0.07 vs. 0.85 0.27] FSH/LH[1.04 0.23

vs. 1.21 0.21] LH [6.34 1.68 vs. 5.38 1.43] P 0.05

[0.67 0.71 vs. 1.13 0.68] P 0.05 :

-35

R259.117.5 A 1674-8999(2014)07-1029-03

1674 6449(2014)06 0669 02

Clinical observation of administration of Xuanju capsule combined with Diane-35 and letrozol on polycystic Ovarian Syndrome

XU An-ran Li Yue HAO Tian-yu*

The General Hospital of Jinan Military Command Jinan 250031

Abstract Objective To study the clinical efficacy of Xuanju capsule combined with Diane-35 and letrozole treatment of polycystic ovarian syndrome(PCOS). **Methods** 60 patients with polycystic ovarian syndrome were randomly allocated into observation group and control group. The patient in control group were treated with Diane-35 and letrozol. The patient in observation group were treated with Xuanju capsule combined with Diane-35 and letrozol. The LH level, the ratio of FSH/LH, the number of dominant follicles and oocytes ovulated were compared before and after treatment between the two groups. **Results** The levels of LH, FSH/LH were significantly different before and after treatment in observation group (P<0.05). The progesterone levels (0.42 0.07 vs. 0.85 0.27) and FSH/LH (1.04 0.23 vs 1.21 0.21) were significantly lower and LH levels (6.34 1.68 vs 5.38 1.43) were significantly higher after treatment in the control group than those in observation group (P<0.05). The number of oocytes ovulated after treatment in the control group (0.67 0.71 vs 1.13 0.68) were significantly less than that in observation group (P<0.05). **Conclusion:** The effect of Xuanju capsule combined with Diane-35 and letrozole in treatment of polycystic ovarian syndrome is better than Diane-35 and letrozole therapy alone..

Key words: Polycystic ovarian syndrome; Compound Xuan Ju Capsule; Diane-35; Letrozol

polycystic ovarian

PCOS

syndrome PCOS

PCOS

7%

PCOS

1

PCOS 20%~30%^[1] -35

1.1 2012 6 12

PCOS

PCOS 60 2003

PCOS

-35

| | | | | 3 | E2 | P | T |
|---------|----|-----------|--------|---|--------------|------------|------|
| 2 | | PCOS | 1 | | PRL | | |
| | | 2 | | | | | |
| | | 3 | | | | | |
| | | | | | 1.3 | | |
| [2]2006 | | | | | | | 10mL |
| | 1 | 2 | | | 3 | | |
| | | | 3 | | | | |
| | | 6ml | | | | | |
| 2~10mm | 10 | | 3 | | 1.4 | SPSS16.0 | t |
| | | | | | P 0.05 | | |
| | 60 | | | | 2 | | |
| | | | | | 2.1 | | LH |
| 30 | | | | | FSH/LH | | |
| | | | | | | P .05 | P T |
| | | II | | | E2 FSH PRL | | |
| | | | | | | P .05 | 1) |
| 1.2 | | | 3 | | 2.2 | | T |
| -35 | | | | | LH | FSH/LH | |
| 21d | | 3 | 3 | | | P .05 | |
| | 4 | 3 | | | P E2 FSH PRL | | |
| | | 2 | 1 | | | P .05)(2) | |
| 5d | | 3 | | - | 2.3 | | |
| 35 | 1 | 21d | | | | | |
| | | | | | P LH | FSH/LH | |
| | | | | | | P 0.05 | |
| | | Z20060462 | | 3 | | P .05 | |
| | 3 | 20d | | 3 | 20 | 1~3 | |
| | 3 | | 4 | 3 | 16 | 1~2 4 | 10 |
| | | | 2 | 1 | | | 27 |
| | 5d | | | | 1~3 | | 26 |
| | | | | | 1~3 1 | 3 | |
| -35 | | -35 | | | | | |
| | | | | | P 0.05 | | |
| FSH | | LH | FSH LH | | P 0.05 | 3 | |

| | | 1 | | $\bar{X} \pm s$ | | | | | | | | | | |
|----|------------------------------|----------|----------------------------|-----------------|--------|-------|-------------------------------|-------|------------------------------|------|-----------------------------|------|------------------------------|------|
| | | *P 0.05. | | | | | | | | | | | | |
| n | FSH (IU L ⁻¹) | | LH (U L ⁻¹) | | LH/FSH | | E2 (mol L ⁻¹) | | P (nmol L ⁻¹) | | T (nmolL ⁻¹) | | PRL (mU L ⁻¹) | |
| 30 | 5.81 | 1.52 | 8.63 | 2.08 | 0.72 | 0.33 | 32.10 | 16.40 | 0.41 | 0.07 | 0.40 | 0.12 | 15.64 | 4.32 |
| 30 | 6.30 | 0.85 | 6.34 | 1.68* | 1.04 | 0.26* | 31.40 | 16.09 | 0.42 | 0.07 | 0.36 | 0.12 | 14.92 | 3.91 |

| | | 2 | | $\bar{X} \pm s$ | | | | | | | | | | |
|----|------------------------------|----------|----------------------------|-----------------|--------|------|-------------------------------|-------|------------------------------|--|-----------------------------|--|------------------------------|--|
| | | *P 0.05. | | | | | | | | | | | | |
| n | FSH (IU L ⁻¹) | | LH (U L ⁻¹) | | LH/FSH | | E2 (mol L ⁻¹) | | P (nmol L ⁻¹) | | T (nmolL ⁻¹) | | PRL (mU L ⁻¹) | |
| 30 | 6.03 | 1.52 | 9.65 | 3.87 | 0.72 | 0.33 | 34.43 | 16.28 | | | | | | |

3
 $\bar{X} \pm s$
 *P 0.05

3

PCOS

-35

PCOS

PCOS LH FSH

LH/FSH LH

LHRH [2] -35

LH CC LE PCOS

2000 Mitwally

PCOS Casper^[4-5]

PCOS PCOS CC

[6]

PCOS

PCOS

PCOS

[7-8]

E2

E2

PCOS

OHSS

[14-15]

PCOS

-35

LH

FSH/LH

-35

[9]

[10]

-35

PCOS

[11]

-35

PCOS

PCOS

[12]

PCOS

[13]

P

BBT

[6] , , . [J]. ,2014,23:594-597.

[7] , , . [J]. ,2005,12:6-7.

[8] , . [J]. ,2008,27:138-140.

PCOS

[9] , . [J]. ,2006,25:378.

[10] , . -35 [J]. ,2005,25:794-796.

[11] . -35 30 [J]. ,2008,23:46-47.

[1] , . [M]. 1 . : ,2009,1-8.

[2] . [J]. ,2066,15:261-263

[3]Falsetti L, Gamber A, Tisi G.Efficacy of the combination ethinyl oestradiol and cyproterone acetate on endocrine, clinical and ultrasonographic profile in polycystic ovarian syndrome[J].Hum Reprod,2001,16:36-42.

[4]Mitwally MF,Casper RF. Aromatase Inhibition:A novel method of ovulation induction in women with polycystic ovarian syndrome[J].Reprod Technol, 2000,10:244-247.

[5]Mitwally MF,Casper RF.Use of an aromatase inhibitor for induction of ovulation in patient with an inadequate response to clomiphene citrate[J].Fertil Steril,2001,75:305-309.

[12] , . [J]. ,2011,22:82-84.

[13] , , , . [J]. ,2009,4:799-801.

[14] . [J]. ,2010,19:152-153.

[15] . [J]. ,2008,17:431-434.